Market capitalization | $2.03b |
Enterprise Value | $1.77b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 60.06 |
P/S ratio (TTM) P/S ratio | 68.69 |
P/B ratio (TTM) P/B ratio | 6.91 |
Revenue growth (TTM) Revenue growth | 9,199.68% |
Revenue (TTM) Revenue | $29.48m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
9 Analysts have issued a Geron Corporation forecast:
9 Analysts have issued a Geron Corporation forecast:
Sep '24 |
+/-
%
|
||
Revenue | 29 29 |
9,113%
9,113%
|
|
Gross Profit | 28 28 |
-
|
|
EBITDA | -207 -207 |
15%
15%
|
EBIT (Operating Income) EBIT | -208 -208 |
15%
15%
|
Net Profit | -201 -201 |
15%
15%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Geron Corp. operates as a biotechnology company. It develops a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. The firm develops therapeutic products for oncology. The company was founded by Michael D. West on November 28, 1990 and is headquartered in Menlo Park, CA.
Head office | United States |
CEO | John Scarlett |
Employees | 141 |
Founded | 1990 |
Website | www.geron.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.